Barclays raised the firm’s price target on Fortrea (FTRE) to $8 from $6 and keeps an Underweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea Holdings Appoints William J. Sharbaugh as Director
- Fortrea price target raised to $9.50 from $7 at Jefferies
- Fortrea price target raised to $14 from $9 at Baird
- Fortrea Expands Inducement Award Plan for New Hires
- Cautious Hold Rating for Fortrea Holdings Inc. Amid Revenue Growth and Modest Margins